The median effective concentration of propofol with different doses of dexmedetomidine during gastrointestinal endoscopy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100054402

Enrollment

Unknown

Registered

2021-12-17

Start date

2021-12-20

Completion date

Unknown

Last updated

2022-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pharmacodynamics

Interventions

Experimental group1:Dexmedetomidine 0.5 µg/kg

Experimental group2:1µg/kg dexmedetomidine

Control group:normal saline

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 years; 2. ASA classification is I-III; 3. Body mass index (BMI) 19–27 k.m-2.

Exclusion criteria

Exclusion criteria: 1. The patient is allergic to either propofol or dextromethorphan; 2. Long-term use of painkillers; 3. Alcoholism; 4. Nervous system or schizophrenia; 5. Advanced liver or kidney disease; 6. Sleep apnea syndrome; 7. Uncontrolled hypertension, blood pressure higher than 180/120mmHg; 8. Psychotropic drug users.

Design outcomes

Primary

Measure	Time frame
Blood pressure;heart rate;	—

Countries

China

Contacts

Public ContactYang Hua

Shidong Hospital, Yangpu District, Shanghai

yanghuayanghua1977@163.com+86 21 25066782

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026